REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Launched by UNIVERSITY OF CINCINNATI · Jun 5, 2023

Keywords

ClinConnect Summary

The REDEL Trial is a clinical study looking at how a lower dose of radiation to nearby lymph nodes can help reduce side effects in patients with anal cancer who are also receiving chemotherapy and radiation treatment. Researchers want to see if this reduced radiation approach is just as effective as the standard dose while causing less harm to the patients. The trial is currently recruiting participants who are 18 years or older and have specific types of anal cancer, including locally advanced cases or certain conditions related to HPV.

To be eligible for the trial, patients need to have certain stage cancers confirmed by imaging tests, such as a PET scan or MRI, within the last 60 days. They should also be in good overall health and able to undergo the specified treatments. Participants will receive the reduced radiation along with chemotherapy and will be closely monitored throughout the study to track their response and any side effects. It's important for potential participants to understand the eligibility requirements and discuss this option with their healthcare provider to see if it might be a good fit for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years.
• • 2. Patients must have stage T1-4N+M0 or T3/T4N0M0 locally advanced anal cancer as evidenced by a PET scan AND either a CT with contrast of the abdomen/pelvis or an MRI with contrast of the pelvis. All imaging must be from within 60 days prior to registration.
• • 1. Note: Patients with T2N0 disease will be allowed if the primary tumor is \>4 cm. Patients with Stage I-T1N0M0 or Stage II-T2N0M0 (tumor ≤ 4cm) will be ineligible for participation.
• • 2. Patients with perianal cancer that is HPV associated (P16+) will be eligible if the tumor extends to the anal verge and the CTV will include the mesorectal, internal/external iliac, and inguinal lymph nodes.
• • 3. Patients with excision of the primary tumor but with node positive disease or residual disease at the primary if T3T4N0 will be eligible.
• • 3. ECOG performance status 0 or 1 (or Karnofsky ≥70, see Appendix A).
• • 4. Patients must be able to receive concurrent treatment with capecitabine and Mitomycin C in the opinion of the investigator.
• • 5. Creatinine Clearance must be \> 30 ml/min.
• • 6. Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • 1. Any prior pelvic radiation.
• • 2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine.
• • 3. Patients with uncontrolled intercurrent illness that in the opinion of the investigator would prevent receipt of radiation or capecitabine.
• • a. Note: HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
• • 4. Pregnant or breastfeeding women are excluded from this study.
• • 5. Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the investigator.
• • 6. Patients with active autoimmune or connective tissue disease requiring systemic treatment are excluded from this study.